Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions

May combine two claims.

The protective association between CHIP and AD was strongest among APOE ε3/ε3 individuals, whereas no significant effect was detected in ε2 or ε4 carriers.

“Stratification by APOE genotype indicated that the protective association was strongest among APOE ε3/ε3 individuals, whereas no significant effect was detected in ε2 or ε4 carriers [10].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourceDisputed

  The Results section, “Stratified associations between CHIP and AD” (page unavailable), says the reduction in AD dementia risk was of similar magnitude in APOE ε3/ε3 individuals and ε4 carriers, rather than strongest in ε3/ε3 individuals alone. It also reports lower AD neuropathologic change in both groups; the effect was not seen in the ε2/ε2 or ε2/ε3 groups. The nonsignificant interaction terms do not establish an absence of an effect in ε4 carriers. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

Studies incorporating ultra-deep sequencing that capture very small clones may identify biologically distinct populations, potentially diluting associations or introducing heterogeneity when clones with low VAF and uncertain functional relevance are included.

“In contrast, studies incorporating ultra-deep sequencing approaches that capture very small clones may identify biologically distinct populations, potentially diluting associations or introducing heterogeneity when clones with low VAF and uncertain functional relevance are included [13].”

• cites [13] Choi, J., Park, K.S., Le Guen, Y., Park, J.H., Zhou, Z., Enyenihi, L., Rosen, I., Choi, Y.H., Walsh, C.A., and Kim, J.W. (2025). Clonal Hematopoiesis Mutations Increase Risk of Alzheimer’s Disease with APOE ε3/ε3 Genotype. bioRxiv. sourceDisputed

  Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

CHIP-associated mutations in myeloid cells promote inflammatory signaling and accelerate atherosclerosis, establishing a causal link between somatic mosaicism and chronic disease.

“CHIP-associated mutations in myeloid cells promote inflammatory signaling and accelerate atherosclerosis, establishing a causal link between somatic mosaicism and chronic disease”

• cites [6] Fuster, 2017, Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice, Science sourcePartly supported

  The Abstract reports that TET2-deficient blood cells increased atherosclerotic plaque size in mice, while TET2-deficient macrophages increased NLRP3-mediated IL-1β secretion; it describes this as supporting a causal role in atherosclerosis. The claim generalizes that result from TET2 to CHIP-associated mutations broadly and does not retain the mouse-model qualification. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Microglia play a central role in amyloid clearance, synaptic remodeling, and regulation of inflammatory signaling within the brain.

“When activated, microglia, the resident immune cells of the central nervous system, play a central role in amyloid clearance, synaptic remodeling, and the regulation of inflammatory signaling within the brain [21].”

• cites [21] Yamazaki, 2019, Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies, Nat. Rev. Neurol. sourcePartly supported

  The Aβ clearance section describes microglial uptake and degradation of amyloid, and Neuroinflammation says microglia play a central role in the brain’s immune response and describes their proinflammatory activation. The Synaptic function section discusses APOE-related synaptic changes but does not attribute synaptic remodeling to microglia, so that part of the claim is unsupported. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

CHIP is associated with increased all-cause mortality and a broad spectrum of non-malignant diseases, most prominently atherosclerotic cardiovascular disease and stroke.

“CHIP has emerged as a clinically relevant state associated with increased all-cause mortality and a broad spectrum of non-malignant diseases, most prominently atherosclerotic cardiovascular disease and stroke [1,4,5].”

• cites [1] Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes, N. Engl. J. Med. sourcePartly supported

  The Results sections on overall survival and cardiometabolic disease report increased all-cause mortality and associations with incident coronary heart disease, ischemic stroke, and type 2 diabetes. These support the named outcomes, but the paper does not establish the broader claim of a spectrum of non-malignant diseases beyond those cardiometabolic conditions. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [4] Jaiswal, 2020, Clonal hematopoiesis and nonhematologic disorders, Blood sourceNot checked — no full text of the source
• cites [5] Arends, 2023, Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke, Blood sourceSupported

May combine two claims.

CHIP is strongly and well-established associated with vascular disease, stroke, and cerebrovascular pathology.

“A critical yet underappreciated aspect of this emerging literature is the strong and well-established association of CHIP with vascular disease, stroke, and cerebrovascular pathology [15,16].”

• cites [15] Jaiswal, 2017, Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease, N. Engl. J. Med. sourcePartly supported

  The Results sections on coronary heart disease, early-onset myocardial infarction, and coronary artery calcification report strong associations between CHIP and coronary vascular disease. They do not establish the claimed association with stroke or cerebrovascular pathology; searches for those outcomes found no supporting passage in our copy. Page numbers were not available. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [16] Mayerhofer, 2023, Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke, Stroke sourcePartly supported

  The Introduction reports a higher risk of atherosclerotic cardiovascular disease in CHIP carriers, and the Results find associations with carotid intima-media thickness and aortic plaques in young stroke patients. But the Discussion says the association with stroke etiology was not significant and that CHIP’s role in stroke remains uncertain, so calling the entire association ‘strong and well-established’ overstates this source. Page numbers were not provided in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

AD is increasingly viewed from a geroscience perspective as a multifactorial condition shaped by systemic aging processes, including immune dysregulation, vascular disease, and metabolic dysfunction.

“AD is increasingly viewed from a geroscience perspective as a multifactorial condition shaped by systemic aging processes, including immune dysregulation, vascular disease, and metabolic dysfunction [9].”

• cites [9] Frisoni, 2025, New landscape of the diagnosis of Alzheimer’s disease, Lancet sourcePartly supported

  The risk-factors section (p. 4) identifies older age as the strongest risk factor for sporadic Alzheimer’s disease and lists hypertension, obesity, and diabetes among relevant factors. The trajectories section (p. 5) also says age, frailty, and other factors modulate disease trajectories. The paper does not frame Alzheimer’s disease explicitly from a geroscience perspective or identify immune dysregulation as one of the systemic aging processes shaping it. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Somatic mutations present in the peripheral hematopoietic system could theoretically be imported into the brain's immune environment, posing a mechanistic link between systemic aging and local neuroinflammation.

“any somatic mutations present in the peripheral hematopoietic system could theoretically be imported into the brain’s immune environment, posing a mechanistic link between systemic aging and local neuroinflammation [10,24,25,26].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourcePartly supported

  The Results (Detection of CHIP variants in the human brain) found blood-associated CHIP mutations in a brain cell population, and the Discussion proposes that peripheral myeloid cells may enter the brain. This supports the proposed route from blood to brain, but the paper examines CHIP mutations—not any somatic mutation—and does not establish a mechanistic link to local neuroinflammation. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [24] Zhang, 2025, Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis, Mol. Neurodegener. sourcePartly supported

  The Introduction (page unavailable) says that peripheral immune cells can infiltrate the CNS and exacerbate neuroinflammation. The review does not say that somatic mutations in the peripheral hematopoietic system are carried into the brain or identify that as a mechanism linking systemic aging to local neuroinflammation; searches for somatic mutations and clonal hematopoiesis did not find such a passage. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [25] Di Pietro, A.A., Powley, S., Perciballi, E., Stewart, M., Therrien, M., and Scott-Hewitt, N. (2026). Microglia in systemic neuroimmune communication: Functions beyond phagocytosis. Trends Immunol., Online ahead of print. sourcePartly supported

  In “Microglia Bridge Environmental Exposures and CNS Function” (page unavailable), the paper says aging-related systemic inflammation can amplify inflammatory inputs in the CNS and that immune cells can infiltrate during blood–brain barrier disruption. It does not say that peripheral hematopoietic somatic mutations are imported into the brain or identify that as the mechanism linking aging to local neuroinflammation. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [26] Smyth, 2025, Redefining CNS immune privilege, Nat. Rev. Immunol. sourceNot checked — no full text of the source

May combine two claims.

In mouse models, CHIP-derived myeloid cells can infiltrate the central nervous system and modulate microglial function and amyloid clearance.

“Experimental work in mouse models (such as 5xFAD and APP/PS1), utilizing bone marrow chimeric and parabiosis systems, has further added complexity, demonstrating that CHIP-derived myeloid cells can infiltrate the central nervous system and modulate microglial function and amyloid clearance in these mice [14].”

• cites [14] Matatall, 2025, TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice, Cell Stem Cell sourcePartly supported

  The Results report that Tet2-mutant bone marrow-derived cells infiltrated the brains of 5xFAD mice, alongside changes in microglial populations; the Abstract reports reduced β-amyloid plaque formation. The cited paper used bone marrow transplantation, but the provided evidence does not support the sentence’s reference to parabiosis or to APP/PS1 as a separate mouse model. Its direct test of increased amyloid phagocytosis used human microglia-like cells in vitro, not infiltrating cells in mice. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: Findings from mouse models of AD (5xFAD, APP/PS1) about CHIP-mutated myeloid cells can be extrapolated to human CHIP-AD mechanisms.

May combine two claims.

CHIP-associated mutations alter the behavior of hematopoietic stem cells, and some confer a fitness advantage leading to clonal expansion.

“clonal hematopoiesis-associated mutations alter the behavior of hematopoietic stem cells (HSCs); some also confer a fitness advantage, leading to clonal expansion [27,28].”

• cites [27] Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N. Engl. J. Med. sourceSupported
• cites [28] Bowman, 2018, Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies, Cell Stem Cell sourceSupported

May combine two claims.

TET2-mutant myeloid cells exhibit altered cytokine production, notably IL-1β, and inflammatory signaling, which has been directly linked to increased cardiovascular risk.

“TET2-mutant myeloid cells exhibit altered cytokine production (notably IL-1ß) and inflammatory signaling, which has been directly linked to increased cardiovascular risk [6,31].”

• cites [6] Fuster, 2017, Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice, Science sourceSupported
• cites [31] Challen, 2011, Dnmt3a is essential for hematopoietic stem cell differentiation, Nat. Genet. sourceCould not verify

  The Results section on multipotency gene upregulation examines Dnmt3a-null hematopoietic stem cells and their differentiation-related gene expression. Searches for TET2-mutant myeloid cells, IL-1β, inflammatory signaling, and cardiovascular risk found no passage in our copy addressing the attributed claim. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

ApoE ε4 elevates risk of AD by about three-four-fold, ApoE ε2 is associated with a protective effect, and ApoE ε3 is considered largely neutral.

“While ApoE ε4 eleveates risk of AD by about three–four-fold, ApoE ε2 is associated with a protective effect, and ApoE ε3, as the most prevalent isoform in the general population, is considered largely neutral [23].”

• cites [23] Liu, 2013, Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy, Nat. Rev. Neurol. sourcePartly supported

  The Introduction reports ε3 as the most prevalent allele (77.9%), and the ‘APOE ε4 as a strong risk factor for AD’ section uses ε3/ε3 as the risk reference and reports a protective association for ε2. Its approximately threefold ε4 estimate applies to one-copy carriers among Caucasian subjects (ε3/ε4 OR 3.2); the estimate for ε4/ε4 is OR 14.9. The unqualified three–four-fold figure therefore does not cover all ε4 carriers. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Genome-wide association studies have consistently implicated immune-related pathways in AD susceptibility, particularly those involving microglial function.

“Genome-wide association studies have consistently implicated immune-related pathways in AD susceptibility, particularly those involving microglial function [21,22].”

• cites [21] Yamazaki, 2019, Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies, Nat. Rev. Neurol. sourcePartly supported

  The Neuroinflammation section (page unavailable in our copy) links microglial immune function to AD and reports that a rare TREM2 variant is associated with increased AD risk. It does not say that genome-wide association studies have consistently implicated immune-related pathways; the evidence it presents is narrower than that claim. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [22] Heneka, 2025, Neuroinflammation in Alzheimer disease, Nat. Rev. Immunol. sourceSupported

May combine two claims.

Large-scale epidemiological studies have identified substantial overlap between AD and vascular risk factors, and mixed dementia phenotypes are the rule rather than the exception in older populations.

“Large-scale epidemiological studies have identified substantial overlap between AD and vascular risk factors, and mixed dementia phenotypes are now understood to be the rule rather than the exception in older populations [9].”

• cites [9] Frisoni, 2025, New landscape of the diagnosis of Alzheimer’s disease, Lancet sourcePartly supported

  The Risk and protective factors section (p. 4) identifies several cardiovascular and metabolic factors associated with dementia risk, including hypertension, obesity, diabetes, and high LDL cholesterol. The Incidence and prevalence section (p. 4) says mixed neurodegenerative and vascular dementia becomes increasingly frequent with older age. It does not establish that mixed phenotypes are the rule rather than the exception in older populations, and its risk-factor discussion concerns dementia broadly rather than demonstrating substantial overlap specifically with Alzheimer’s disease. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

The standard diagnostic threshold for CHIP is often set at 2%, but high-sensitivity sequencing can detect small clones at levels as low as 0.5%.

“While the standard diagnostic threshold is often set at 2%, high-sensitivity sequencing can detect small clones at levels as low as 0.5%”

• cites [2] Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood sourcePartly supported

  The “Proposed criteria for CHIP” section proposes a 2% mutant-allele fraction as a working threshold and says deeper sequencing can find smaller mutations. It does not state that high-sensitivity sequencing detects clones at 0.5%; the 0.5% figure in that section concerns annual progression, not detection. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [3] Zink, 2017, Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly, Blood sourcePartly supported

  The Introduction says some investigators proposed a 2% variant-allele-fraction cutoff for an at-risk clinical entity; it does not call this an established diagnostic threshold. Panel resequencing reports detecting variants down to 1%, not 0.5%. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

The prevalence of CHIP increases sharply with age, creating a significant biological intersection between individuals at risk for CHIP and late-onset AD.

“The prevalence of CHIP increases sharply with age, creating a significant biological intersection between individuals at risk for CHIP and late-onset AD [9,32].”

• cites [9] Frisoni, 2025, New landscape of the diagnosis of Alzheimer’s disease, Lancet sourceCould not verify

  The Risk and protective factors section (p. 4) identifies older age as a risk factor for sporadic Alzheimer’s disease, but it does not address CHIP. Searches for “CHIP” and “clonal hematopoiesis” found no passage establishing that CHIP prevalence rises with age or that the two populations overlap. (LLM, conf=0.75)

  Experimental — accuracy not yet measured
• cites [32] Jaiswal, 2019, Clonal hematopoiesis in human aging and disease, Science sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

AD is neuropathologically characterized by accumulation of extracellular amyloid-β plaques and intracellular tau tangles, leading to synaptic dysfunction and progressive neuronal loss.

“AD is neuropathologically characterized by the accumulation of extracellular amyloid-ß plaques and intracellular tau tangles, leading to synaptic dysfunction and progressive neuronal loss [22].”

• cites [22] Heneka, 2025, Neuroinflammation in Alzheimer disease, Nat. Rev. Immunol. sourcePartly supported

  The Introduction identifies extracellular amyloid-β deposits and intraneuronal tau tangles as neuropathological features of AD. The “Synapses and axons” section describes synapse loss and dysfunction in amyloid-β and tau models, and “Microglial senescence” discusses tau-mediated neurodegeneration. These passages do not establish the sentence’s broader, direct claim that plaque and tangle accumulation leads to progressive neuronal loss in AD. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Established risk factors for AD include advanced age >65 years, female sex, and most importantly, the Apolipoprotein E ε4 allele.

“Established risk factors for AD include advanced age > 65 years, female sex, and most importantly, the Apolipoprotein E (ApoE) ε4 allele [20,23].”

• cites [20] Collaborators, 2022, Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019, Lancet Public Health sourcePartly supported

  The Results (page unavailable) report that dementia prevalence increases with age and is higher in women than in men, supporting those parts of the claim at the broader dementia level. The paper does not establish a risk threshold of >65 years for Alzheimer’s disease or identify the ApoE ε4 allele as its most important risk factor; ApoE appears only in the title of a cited study in the References (page unavailable). (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [23] Liu, 2013, Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy, Nat. Rev. Neurol. sourcePartly supported

  The Introduction reports that AD prevalence rises from about 13% after age 65 to 45% after age 85. The section “APOE ε4 as a strong risk factor for AD” calls ε4 the strongest *genetic* risk factor, not the most important risk factor overall. Our copy does not establish female sex as an AD risk factor (searched: female sex, women, female). Page numbers were not available in the indexed passages. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

During neurodegeneration, blood-brain barrier integrity declines, which may facilitate peripheral monocytes to infiltrate the CNS and differentiate into microglia-like cells.

“during neurodegeneration, the integrity of the blood–brain barrier declines. This may facilitate debated levels of peripheral monocytes to infiltrate the central nervous system and differentiate into microglia-like cells.”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourcePartly supported

  The Discussion (page unavailable) proposes that peripherally derived myeloid cells may enter the brain, and the Results describe MG-like cells in brain samples. But the paper does not say that blood–brain barrier integrity declines during neurodegeneration or that such a decline enables entry; it also does not establish that the cells are infiltrating monocytes that differentiate into MG-like cells. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [24] Zhang, 2025, Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis, Mol. Neurodegener. sourcePartly supported

  The Introduction (page unavailable) says that BBB compromise in Alzheimer’s disease facilitates peripheral immune-cell infiltration into the CNS. The “Other peripheral immune cells” section (page unavailable) reports monocyte-derived macrophages infiltrating the brain in late-stage AD, but does not say infiltrating monocytes differentiate into microglia-like cells; it treats peripheral monocytes and resident microglia as distinct. The claim also generalizes beyond the paper’s AD focus. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [25] Di Pietro, A.A., Powley, S., Perciballi, E., Stewart, M., Therrien, M., and Scott-Hewitt, N. (2026). Microglia in systemic neuroimmune communication: Functions beyond phagocytosis. Trends Immunol., Online ahead of print. sourcePartly supported

  The section “Microglia Bridge Environmental Exposures and CNS Function” (page unavailable) says immune cells can infiltrate during blood–brain barrier disruption. It does not say that barrier integrity declines during neurodegeneration or that infiltrating peripheral monocytes differentiate into microglia-like cells. The “Microglial State-of-Mind” section (page unavailable) instead distinguishes microglia from peripheral infiltrating macrophages. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [26] Smyth, 2025, Redefining CNS immune privilege, Nat. Rev. Immunol. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

CHIP prevalence reaches approximately 39% in individuals older than 60 years when high-sensitivity sequencing with VAF greater than 0.5% is used.

“reaching approximately 39% in individuals older than 60 years when utilizing high-sensitivity sequencing (Variant Allele Fraction (VAF) greater than 0.5%) [2,3]”

• cites [2] Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood sourcePartly supported

  The section on somatic mutations in apparently healthy persons reports that clonal hematopoiesis becomes more common with age, including a prevalence of 10% among people over 65. It does not report approximately 39% among people over 60 using sequencing with VAF greater than 0.5%. The Proposed criteria for CHIP section instead uses a working threshold of at least 2% VAF (page numbers unavailable in our copy). (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [3] Zink, 2017, Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly, Blood sourcePartly supported

  The ‘Clonal hematopoiesis is very common in the elderly’ section reports that detection rises with age and exceeds 50% after age 85, supporting the broad prevalence point. It does not report approximately 39% for people over 60. The ‘Identification of mosaic somatic mutations’ section gives a lower WGS detection limit of VAF 0.1, while ‘Panel resequencing’ reports calls down to VAF 0.01—not the claimed 0.5% threshold. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

CHIP is an age-related condition affecting over 10-20% of individuals older than 70 years.

“Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition affecting over 10–20% of individuals older than 70 years”

• cites [2] Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood sourceSupported
• cites [3] Zink, 2017, Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly, Blood sourcePartly supported

  The section ‘Clonal hematopoiesis is very common in the elderly’ reports that clonal hematopoiesis increases with age and exceeds 50% among people older than 85. It does not establish the claimed 10–20% prevalence for CHIP specifically among people older than 70; its whole-genome measure includes cases without candidate driver mutations. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Protection from AD was primarily driven by larger clones (>8% VAF), with weaker effects observed at lower VAF thresholds (>2%).

“Protection from AD was primarily driven by larger clones (>8%), with weaker effects observed at lower VAF thresholds (>2%) [10].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourceSupported

May combine two claims.

Choi et al. reported an increased incidence of CHIP in AD cases compared with controls (n = 289), with effects driven specifically by APOE ε3/ε3 individuals.

“Choi et al. reported an increased incidence of CHIP in AD cases compared with controls (n = 289), with effects driven specifically by APOE ε3/ε3 individuals [13].”

• cites [13] Choi, J., Park, K.S., Le Guen, Y., Park, J.H., Zhou, Z., Enyenihi, L., Rosen, I., Choi, Y.H., Walsh, C.A., and Kim, J.W. (2025). Clonal Hematopoiesis Mutations Increase Risk of Alzheimer’s Disease with APOE ε3/ε3 Genotype. bioRxiv. sourcePartly supported

  The Abstract (page not indicated) reports a higher burden of CHIP mutations in AD cases than controls, driven by APOE ε3/ε3 individuals. However, it gives 298 blood samples, not 289; the Sample information section confirms 108 AD patients and 190 controls. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

May combine two claims.

Aging, vascular dysfunction, and chronic neuroinflammation compromise blood-brain barrier integrity, leading to increased trafficking of peripheral immune cells and microglial replacement.

“aging, vascular dysfunction, and chronic neuroinflammation are known to compromise the integrity of the blood–brain barrier. This can lead to increased trafficking of peripheral immune cells as well as the above-mentioned microglial replacement of resident microglia by peripheral monocytes [24,36].”

• cites [24] Zhang, 2025, Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis, Mol. Neurodegener. sourcePartly supported

  The Introduction states that compromised blood–brain barrier integrity facilitates peripheral immune-cell infiltration, and “Other peripheral immune cells” discusses replacement of resident microglia by peripheral monocytes in Alzheimer’s mouse models. The copy does not establish the claimed chain in which aging, vascular dysfunction, and chronic neuroinflammation compromise the barrier and thereby cause microglial replacement; the CD8+ T-cell section instead describes vascular dysfunction as a consequence of amyloid-associated barrier damage. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [36] Ginhoux, 2010, Fate mapping analysis reveals that adult microglia derive from primitive macrophages, Science sourcePartly supported

  The paper’s results (section labeled Abstract; page unavailable) report some donor-derived microglia in irradiated bone-marrow chimeras and suggest that radiation-induced brain injury enables recruitment of bone-marrow-derived cells. They do not establish that aging, vascular dysfunction, or chronic neuroinflammation compromise the blood–brain barrier or cause peripheral monocytes to replace resident microglia. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

Both Bouzid et al. and Choi et al. relied on the ADSP as a validation cohort yet arrived at strikingly opposed conclusions, underscoring the sensitivity of inferred CHIP effects to methodological heterogeneity.

“Notably, both studies relied on the ADSP as a validation cohort yet arrived at strikingly opposed conclusions, underscoring the sensitivity of inferred CHIP effects to methodological heterogeneity.”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourcePartly supported

  The Results (Association between CHIP and AD dementia; page not provided) confirm that Bouzid et al. used ADSP to replicate their finding and reported a lower risk of AD dementia among CHIP carriers. The Methods (Statistical analysis plan; page not provided) discuss how selection and sequencing differences can affect CHIP analyses. Our copy does not establish that Choi et al. also used ADSP or reached an opposed conclusion, so it cannot substantiate the comparison between the two studies. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [13] Choi, J., Park, K.S., Le Guen, Y., Park, J.H., Zhou, Z., Enyenihi, L., Rosen, I., Choi, Y.H., Walsh, C.A., and Kim, J.W. (2025). Clonal Hematopoiesis Mutations Increase Risk of Alzheimer’s Disease with APOE ε3/ε3 Genotype. bioRxiv. sourcePartly supported

  The ADSP analysis section confirms that Choi et al. used ADSP data and compared their analysis with Bouzid et al.’s work in an ADSP cohort. The paper discusses conflicting findings and possible methodological explanations, but does not establish that Bouzid and Choi reached strikingly opposed conclusions; it instead says their odds ratios were similar in the ADSP WES ε3/ε3 European subgroup. No page number is available in our copy. (LLM, conf=0.83)

  Experimental — accuracy not yet measured

May combine two claims.

Gene-specific effects, clonal burden, host genetic background, and neurovascular integrity all shape whether CHIP-derived immune cells exert protective or pathogenic influences in the aging brain.

“Gene-specific effects, clonal burden, host genetic background, and neurovascular integrity all shape whether CHIP-derived immune cells exert protective or pathogenic influences in the aging brain [10,11,13,19,33,34].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourcePartly supported

  The Results (Association between CHIP and AD dementia; Stratified associations between CHIP and AD) link greater clonal burden to lower AD risk and report suggestive differences by APOE genotype. The Discussion reports similar protective associations across several driver genes, rather than established gene-specific protective or pathogenic effects. The paper does not show that neurovascular integrity determines these effects, and it cautions that the infiltrating cells’ protective mechanism remains unproven. (LLM, conf=0.89)

  Experimental — accuracy not yet measured
• cites [11] Liu, 2024, Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases, J. Intern. Med. sourceNot checked — no full text of the source
• cites [13] Choi, J., Park, K.S., Le Guen, Y., Park, J.H., Zhou, Z., Enyenihi, L., Rosen, I., Choi, Y.H., Walsh, C.A., and Kim, J.W. (2025). Clonal Hematopoiesis Mutations Increase Risk of Alzheimer’s Disease with APOE ε3/ε3 Genotype. bioRxiv. sourcePartly supported

  The Abstract reports that CHIP mutation burden in Alzheimer’s patients differs by APOE genotype and identifies enrichment in particular CHIP genes. The discussion (section labeled “127”) says blood-derived cells may enter the aging brain when blood–brain barrier integrity is compromised. But the paper does not establish that these four factors determine whether CHIP-derived brain immune cells are protective or pathogenic; it reports an association with AD risk and proposes a possible pathogenic mechanism. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [19] Xiao, 2024, Clonal hematopoiesis of indeterminate potential is associated with reduced risk of cognitive impairment in patients with chronic kidney disease, Alzheimers Dement. sourcePartly supported

  The Results section reports differences in cognitive-impairment associations by clone size and some differences by driver gene. Its APOE analysis found only a marginally significant interaction and calls for caution. The paper does not establish that these factors—or neurovascular integrity—determine whether CHIP-derived immune cells are protective or pathogenic; the Discussion says the study cannot determine causality and that the cellular mechanisms remain unknown. Page numbers were not available in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [33] Jakubek, 2025, Clonal hematopoiesis of indeterminate potential and the risk of cognitive impairment in the Women’s Health Initiative Memory Study, Alzheimers Dement. sourcePartly supported

  The Discussion (page not provided) reports that associations with cognitive impairment varied by CHIP driver gene, clone size, and APOE genotype. It does not establish that neurovascular integrity determines whether CHIP-derived immune cells are protective or pathogenic, or demonstrate that these factors causally shape the cells’ effects in the brain. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [34] Naito, T., Hirata, K., Jang, B., Lakhani, C.M., Buonfiglioli, A., Lee, W.P., Valladares, O., Wang, L.S., Okada, Y., and Won, H.H. (2025). Mosaic chromosomal alterations in blood are associated with an increased risk of Alzheimer’s disease. medRxiv. sourcePartly supported

  The Main section (page unavailable) reports differing associations for CHIP and other forms of clonal hematopoiesis with Alzheimer’s disease. It also finds that mCA-associated risk varies by APOE genotype and number of mCAs. Those findings lend partial support to the proposed role of genetic background and burden, but the paper does not establish that gene-specific CHIP effects or neurovascular integrity determine whether CHIP-derived brain immune cells are protective or pathogenic. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

In atherosclerosis, TET2-deficient macrophages overproduce pro-inflammatory cytokines, including interleukin-1β and interleukin-6, via enhanced NLRP3 inflammasome activation, which accelerates plaque instability and vascular injury.

“In the context of atherosclerosis, these cells overproduce pro-inflammatory cytokines, including interleukin-1β and interleukin-6, via enhanced NLRP3 inflammasome activation, which accelerates plaque instability and vascular injury [15,40]”

• cites [15] Jaiswal, 2017, Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease, N. Engl. J. Med. sourcePartly supported

  The Results section reports increased IL-1β and IL-6 expression in Tet2-deficient macrophages, with robust secretion after endotoxin exposure but not LDL exposure; it also reports larger atherosclerotic lesions in mice. The Discussion mentions inflammasome activation, but does not identify NLRP3. Neither passage establishes that this cytokine pathway accelerates plaque instability or vascular injury. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [40] Sano, 2018, Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome, J. Am. Coll. Cardiol. sourcePartly supported

  The Introduction reports greater IL-1β secretion by Tet2-deficient macrophages and increased plaque size in hyperlipidemic mice, with NLRP3 inhibition reducing the plaque-size difference. The Discussion also links Tet2 to repression of LPS-induced IL-6, but does not say IL-6 overproduction occurs through NLRP3 activation. Neither passage establishes plaque instability or vascular injury; the reported atherosclerosis outcome is plaque size. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

Large CHIP clones in the ADSP cohort have been associated with reduced AD risk and attenuated neuropathology, while smaller clones, mosaic chromosomal alterations, and specific genetic contexts may have increased susceptibility.

“While large CHIP clones in the ADSP cohort have been associated with a reduced AD risk and attenuated neuropathology [10], smaller clones, mosaic chromosomal alterations [34], and specific genetic contexts, most notably APOE stratification, may have increased susceptibility [13].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourceSupported
• cites [13] Choi, J., Park, K.S., Le Guen, Y., Park, J.H., Zhou, Z., Enyenihi, L., Rosen, I., Choi, Y.H., Walsh, C.A., and Kim, J.W. (2025). Clonal Hematopoiesis Mutations Increase Risk of Alzheimer’s Disease with APOE ε3/ε3 Genotype. bioRxiv. sourceSupported
• cites [34] Naito, T., Hirata, K., Jang, B., Lakhani, C.M., Buonfiglioli, A., Lee, W.P., Valladares, O., Wang, L.S., Okada, Y., and Won, H.H. (2025). Mosaic chromosomal alterations in blood are associated with an increased risk of Alzheimer’s disease. medRxiv. sourceSupported

May combine two claims.

In the cerebral circulation, CHIP-associated processes manifest as increased risk of ischemic stroke, white matter hyperintensities, lacunar infarcts, and microvascular injury, which are hallmarks of cerebral small vessel disease strongly associated with cognitive decline and executive dysfunction.

“In the cerebral circulation, these processes manifest as increased risk of ischemic stroke, white matter hyperintensities, lacunar infarcts, and microvascular injury, which are hallmarks of cerebral small vessel disease strongly associated with cognitive decline and executive dysfunction [16,17].”

• cites [16] Mayerhofer, 2023, Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke, Stroke sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [17] Ungvari, A., Kállai, A., Stankovics, L., Lendvai-Emmert, D., Gulej, R., Pal, E., Patai, R., Csik, B., Fekete, M., and Lipecz, Á. (2025). Age-Related Alterations of Cerebral Autoregulation. Life, 15. sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

CHIP carriers displayed lower CERAD scores, representing reduced burden of neuritic amyloid plaque and reduced Braak staging, indicating less advanced regional progression and severity of tau pathology.

“CHIP carriers displayed lower Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) scores, representing a reduced burden of neuritic amyloid plaque and reduced Braak staging. These factors indicate less advanced regional progression and severity of tau pathology [10].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourceSupported

May combine two claims.

In 5xFAD and APP/PS1 mouse models, TET2-deficient monocytes exhibit a fitness advantage, infiltrating the brain to differentiate into microglia-like cells.

“In 5xFAD and APP/PS1 mouse models, TET2-deficient monocytes exhibit a fitness advantage, infiltrating the brain to differentiate into microglia-like cells (MLCs).”

• cites [14] Matatall, 2025, TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice, Cell Stem Cell sourcePartly supported

  The Results sections on infiltration and peripherally derived microglia-like cells report more monocytes and macrophages in Tet2-mutant 5xFAD mouse brains and more donor-derived cells with a microglia-like phenotype. The study used noncompetitive bone-marrow transplants, so these findings do not establish a monocyte fitness advantage. Our copy does not report the same finding in a separate APP/PS1 model or establish that the microglia-like cells specifically arose from monocytes. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: Findings from mouse models of AD (5xFAD, APP/PS1) about CHIP-mutated myeloid cells can be extrapolated to human CHIP-AD mechanisms.

May combine two claims.

CHIP-associated mutations in genes such as DNMT3A, TET2, and ASXL1 promote chronic inflammation, endothelial dysfunction, and accelerated atherogenesis through altered myeloid cell function and cytokine signaling.

“CHIP-associated mutations in genes such as DNMT3A, TET2, and ASXL1 promote chronic inflammation, endothelial dysfunction, and accelerated atherogenesis through altered myeloid cell function and cytokine signaling [7,15,43]”

• cites [7] Trowbridge, 2023, Clonal hematopoiesis, aging and Alzheimer’s disease, Nat. Med. sourceNot checked — no full text of the source
• cites [15] Jaiswal, 2017, Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease, N. Engl. J. Med. sourcePartly supported

  The Results link DNMT3A, TET2, and ASXL1 mutations to increased coronary risk, while the mouse and macrophage findings support accelerated atherogenesis and inflammatory signaling specifically for Tet2 loss. The Discussion says it remains unclear whether DNMT3A and ASXL1 act through inflammation; it proposes effects on monocyte recruitment but does not establish endothelial dysfunction. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [43] Libby, 2019, Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week, J. Am. Coll. Cardiol. sourcePartly supported

  In “Potential mechanisms by which CHIP mutations augment cardiovascular risk” (page unavailable), the review reports that Tet2-mutant blood cells increase inflammatory cytokines and that Tet2 mutations accelerate atherosclerotic lesions in susceptible mice. It lists DNMT3A and ASXL1 as CHIP genes, but does not establish the same inflammatory mechanism for them. It raises endothelial injury as a possible consequence rather than demonstrating the claimed endothelial dysfunction. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

TET2-mutant microglia-like cells lead to a significant reduction in Aβ plaque burden and disease progression.

“These factors lead to a significant reduction in Aß plaque burden and disease progression [14].”

• cites [14] Matatall, 2025, TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice, Cell Stem Cell sourcePartly supported

  The Results section ('Loss of Tet2 but not Dnmt3a in peripheral immune cells improves AD pathogenesis'; page unavailable) reports significantly fewer β-amyloid plaques and improved memory in LPS-treated mice transplanted with Tet2-mutant bone marrow. However, the paper does not establish that microglia-like cells themselves caused those outcomes: its microglia-like-cell experiments show increased amyloid phagocytosis in vitro. The plaque and memory differences were not significant in mice without LPS treatment. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: Findings from mouse models of AD (5xFAD, APP/PS1) about CHIP-mutated myeloid cells can be extrapolated to human CHIP-AD mechanisms.

May combine two claims.

In the Women's Health Initiative Memory Study, larger CHIP clones (≥8% VAF) were associated with a significantly reduced risk of clinically diagnosed probable dementia over up to 25 years, but no association was observed for mild cognitive impairment.

“In the Women’s Health Initiative Memory Study, larger CHIP clones (≥8% VAF) were associated with a significantly reduced risk of clinically diagnosed probable dementia over a long-term follow-up of up to 25 years. By contrast, no association was observed for mild cognitive impairment [33].”

• cites [33] Jakubek, 2025, Clonal hematopoiesis of indeterminate potential and the risk of cognitive impairment in the Women’s Health Initiative Memory Study, Alzheimers Dement. sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

CHIP robustly increases the risk of atherosclerotic cardiovascular disease, ischemic stroke, and cerebral small vessel disease, conditions that independently contribute to cognitive impairment and dementia.

“CHIP robustly increases the risk of atherosclerotic cardiovascular disease, ischemic stroke, and cerebral small vessel disease, conditions that independently contribute to cognitive impairment and dementia [4,5,15,16].”

• cites [4] Jaiswal, 2020, Clonal hematopoiesis and nonhematologic disorders, Blood sourceNot checked — no full text of the source
• cites [5] Arends, 2023, Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke, Blood sourcePartly supported

  The Introduction reports an increased ischemic-stroke risk in people with clonal hematopoiesis, and the baseline-characteristics and white-matter-lesion sections find associations with large-artery atherosclerosis and lesions considered a marker of small-vessel disease. But this stroke-patient study does not establish that CHIP causally increases the risk of all three conditions; the white-matter-lesion section only links those lesions to neurodegenerative conditions, not that all three independently contribute to cognitive impairment and dementia. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [15] Jaiswal, 2017, Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease, N. Engl. J. Med. sourcePartly supported

  The Results section ('CHIP associates with coronary heart disease') reports a 1.9-fold greater risk of incident coronary heart disease, and the Discussion links CHIP to atherosclerosis. The cited paper does not establish the sentence’s additional claims about ischemic stroke, cerebral small vessel disease, cognitive impairment, or dementia. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [16] Mayerhofer, 2023, Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke, Stroke sourcePartly supported

  The Introduction reports a higher risk of atherosclerotic cardiovascular disease in CHIP carriers and cites evidence of increased small-vessel ischemic stroke risk. The Results find more atherosclerotic disease among patients with CHIP, but the Discussion cautions that its causal role in stroke remains uncertain. The paper does not establish increased risk of cerebral small vessel disease as distinct from small-vessel stroke, or address whether these conditions independently contribute to cognitive impairment and dementia (no page numbers provided). (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

CHIP-derived myeloid cells can directly integrate into the central nervous system and may participate actively in neuroimmune processes relevant to AD pathogenesis.

“This presence confirms that CHIP-derived myeloid cells can directly integrate into the central nervous system and may participate actively in neuroimmune processes relevant to AD pathogenesis [10,37].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourceSupported
• cites [37] Prinz, 2021, Microglia and Central Nervous System-Associated Macrophages-From Origin to Disease Modulation, Annu. Rev. Immunol. sourcePartly supported

  The Ontogeny and Fate of CNS Macrophages section reports that blood- or bone-marrow-derived myeloid cells can engraft in the CNS, notably after irradiation or microglial depletion. The Myeloid Cells in CNS Inflammation section describes recruited monocytes contributing to inflammation in EAE. Neither passage identifies those cells as CHIP-derived or establishes their participation in Alzheimer’s disease pathogenesis. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

Post-mortem analyses by Bouzid et al. demonstrated that a subset of microglia from CHIP carriers harbored identical somatic mutations compared to those observed in peripheral blood, with mutation frequencies correlating with peripheral clonal burden.

“Post-mortem analyses by Bouzid et al. demonstrated that a subset of microglia from CHIP carriers harbored identical somatic mutations compared to those observed in peripheral blood, with mutation frequencies correlating with peripheral clonal burden [10].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourceSupported

May combine two claims.

Vascular brain injury lowers cognitive reserve and amplifies the clinical expression of neurodegenerative pathology, complicating the distinction between AD and VCID.

“vascular brain injury lowers cognitive reserve and amplifies the clinical expression of neurodegenerative pathology, complicating the distinction between AD and VCID [9].”

• cites [9] Frisoni, 2025, New landscape of the diagnosis of Alzheimer’s disease, Lancet sourcePartly supported

  The section on excluding non-neurodegenerative causes of cognitive impairment (p. 8) identifies small-vessel cerebrovascular disease as a possible cause of cognitive impairment and says MRI is key to the differential diagnosis. It does not say that vascular brain injury lowers cognitive reserve or amplifies the clinical expression of neurodegenerative pathology, so those mechanisms are unsupported. (LLM, conf=0.83)

  Experimental — accuracy not yet measured

May combine two claims.

Current consensus criteria emphasize that "pure" AD is relatively uncommon in advanced age, with most individuals exhibiting overlapping vascular, inflammatory, and neurodegenerative processes.

“Current consensus criteria emphasize that “pure” AD is relatively uncommon in advanced age, with most individuals exhibiting overlapping vascular, inflammatory, and neurodegenerative processes [9].”

• cites [9] Frisoni, 2025, New landscape of the diagnosis of Alzheimer’s disease, Lancet sourcePartly supported

  In “Biomarker use in the clinic” (p. 11), the paper says that multiple pathologies co-occurring with Alzheimer’s disease are the rule, particularly in the oldest-old. “Incidence and prevalence of Alzheimer’s disease” (p. 4) also says mixed neurodegenerative and vascular forms become more frequent with age. These passages support the point that ‘pure’ AD is uncommon at advanced ages, but do not establish that most individuals have overlapping inflammatory processes. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Identical mCA clones were identified within a subset of brain-resident microglia exhibiting a pro-inflammatory transcriptional profile, providing direct evidence that large-scale somatic mosaicism in the blood can mirror pathological immune states in the CNS.

“the study identified identical mCA clones within a subset of brain-resident microglia that exhibited a pro-inflammatory transcriptional profile characterized by the upregulation of MHC-II processing genes and markers of cellular senescence, providing direct evidence that large-scale somatic mosaicism in the blood can mirror pathological immune states in the CNS [34].”

• cites [34] Naito, T., Hirata, K., Jang, B., Lakhani, C.M., Buonfiglioli, A., Lee, W.P., Valladares, O., Wang, L.S., Okada, Y., and Won, H.H. (2025). Mosaic chromosomal alterations in blood are associated with an increased risk of Alzheimer’s disease. medRxiv. sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

Autosomal mosaic chromosomal alterations are associated with increased AD risk and are detectable in both blood and brain-resident microglia, implicating shared vascular and immune mechanisms.

“Recent whole-genome sequencing analyses demonstrate that autosomal mosaic chromosomal alterations are also associated with increased AD risk and are detectable in both blood and brain-resident microglia, implicating shared vascular and immune mechanisms [34,46].”

• cites [34] Naito, T., Hirata, K., Jang, B., Lakhani, C.M., Buonfiglioli, A., Lee, W.P., Valladares, O., Wang, L.S., Okada, Y., and Won, H.H. (2025). Mosaic chromosomal alterations in blood are associated with an increased risk of Alzheimer’s disease. medRxiv. sourcePartly supported

  The Abstract and Main section report an association between autosomal mCAs in blood and increased AD risk, and identify brain microglia-annotated cells carrying the same alterations. They suggest a possible effect on local immune response, but do not establish a shared vascular mechanism. The Main section also cautions that contamination by circulating blood cells cannot be ruled out, so the finding does not establish that the altered cells are brain-resident microglia. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [46] Sarkisyan, 2025, Loss of Y chromosome in Alzheimer’s patients co-occurs with somatic mutations beyond CHIP drivers, Life Sci. AllianceNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

CHIP-associated mutations can be detected in microglia resident in the brain and correlate with peripheral clonal burden, but this phenomenon appears to fluctuate and is context-dependent.

“While recent evidence demonstrates that CHIP-associated mutations can be detected in microglia resident in the brain and correlate with peripheral clonal burden, this phenomenon appears to fluctuate and is context-dependent [10,34].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourcePartly supported

  The Results section on single-nucleus chromatin accessibility profiling reports CHIP-mutated microglia-like cells and a strong correlation between their proportion in occipital cortex and the mutant-cell proportion in peripheral blood. It also reports different proportions across three brain regions in one donor, supporting regional variation. The paper does not show that the phenomenon fluctuates over time; its Discussion raises context-dependent microglial phenotypes as a possibility rather than an established finding. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [34] Naito, T., Hirata, K., Jang, B., Lakhani, C.M., Buonfiglioli, A., Lee, W.P., Valladares, O., Wang, L.S., Okada, Y., and Won, H.H. (2025). Mosaic chromosomal alterations in blood are associated with an increased risk of Alzheimer’s disease. medRxiv. sourcePartly supported

  The Main section reports the same blood mosaic chromosomal alterations (mCAs) in microglia-annotated cells and a correlation in their cell fractions in the primary dataset, but not in the replication dataset. It attributes the finding about CHIP mutations to a previous study; its own correlated finding concerns mCAs, not CHIP-associated mutations. The limitations section also says circulating-blood-cell contamination cannot be ruled out, so residence in brain microglia is not established, and the cross-sectional results do not show fluctuation over time. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

CHIP-mutated clones not only populate the brain's immune compartment but can exhibit a higher variant allele fraction within the isolated microglial pool than in the peripheral blood.

“In contrast to earlier assumptions of restricted infiltration, it has been demonstrated that CHIP-mutated clones not only populate the brain’s immune compartment but can exhibit a higher variant allele fraction (VAF) within the isolated microglial pool than in the peripheral blood [10].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourcePartly supported

  The Results sections on detection of CHIP variants in the human brain and single-nucleus profiling report CHIP variants in a microglia-enriched brain fraction and estimate that 30%–95% of microglia carried a mutation. They report a strong correlation with the mutant-cell fraction in blood, but do not establish a higher VAF in an isolated microglial pool than in peripheral blood; the paper also notes that the sorted fraction contained many nonmicroglial cells. Page numbers were not provided in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

These somatic clones integrate into the neuroinflammatory landscape and potentially outcompete wild-type cells under pathological conditions.

“indicating that these somatic clones integrate into the neuroinflammatory landscape and potentially outcompete wild-type cells under pathological conditions [34].”

• cites [34] Naito, T., Hirata, K., Jang, B., Lakhani, C.M., Buonfiglioli, A., Lee, W.P., Valladares, O., Wang, L.S., Okada, Y., and Won, H.H. (2025). Mosaic chromosomal alterations in blood are associated with an increased risk of Alzheimer’s disease. medRxiv. sourcePartly supported

  The Main section (page not provided) finds blood-associated chromosomal alterations in microglia-annotated brain cells and enrichment of those cells in a redox-related microglial state, supporting their presence in the brain’s disease-relevant cellular landscape. It does not show that the clones outcompete wild-type cells under pathological conditions. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Protective associations with AD and attenuated neuropathology were observed predominantly in individuals carrying large CHIP clones, typically defined by VAF thresholds of ≥8%, whereas smaller clones showed weaker, null, or inconsistent associations.

“In particular, protective associations with AD and attenuated neuropathology were observed predominantly in individuals carrying large CHIP clones, typically defined by VAF thresholds of ≥8%; however, smaller clones showed weaker, null, or inconsistent associations [10,33].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourceSupported
• cites [33] Jakubek, 2025, Clonal hematopoiesis of indeterminate potential and the risk of cognitive impairment in the Women’s Health Initiative Memory Study, Alzheimers Dement. sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

The diagnosis of clinical Alzheimer's disease often encompasses a spectrum of mixed pathologies, particularly in older adults, where VCID frequently coexists with amyloid and tau pathology.

“The diagnosis of clinical Alzheimer’s disease often encompasses a spectrum of mixed pathologies, particularly in older adults, where VCID frequently coexists with amyloid and tau pathology [9].”

• cites [9] Frisoni, 2025, New landscape of the diagnosis of Alzheimer’s disease, Lancet sourcePartly supported

  The Incidence and prevalence section (p. 4) describes mixed Alzheimer’s disease with other pathologies and says mixed neurodegenerative and vascular dementia becomes increasingly frequent with older age. The Alzheimer’s pathology section (p. 2) identifies amyloid and tau as Alzheimer’s pathology. The paper does not specifically say that VCID frequently coexists with both pathologies, so the claim is more specific than the evidence. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

Several studies report that the CHIP-associated risk of AD differs substantially by APOE genotype, with effects appearing most pronounced in individuals with APOE ε3/ε3.

“Several studies report that the CHIP-associated risk of AD differs substantially by APOE genotype, with effects appearing most pronounced in individuals with APOE ε3/ε3 [10,13].”

• cites [10] Bouzid, 2023, Clonal hematopoiesis is associated with protection from Alzheimer’s disease, Nat. Med. sourcePartly supported

  The Results section, “Stratified associations between CHIP and AD,” reports an apparent difference by APOE genotype: the protective association was seen in ε3/ε3 and ε4 carriers, but not in ε2/ε2 or ε2/ε3 carriers. It says the association was of similar magnitude in ε3/ε3 and ε4 carriers, not most pronounced in ε3/ε3, and cautions that the interaction terms were not statistically significant and the findings require confirmation. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [13] Choi, J., Park, K.S., Le Guen, Y., Park, J.H., Zhou, Z., Enyenihi, L., Rosen, I., Choi, Y.H., Walsh, C.A., and Kim, J.W. (2025). Clonal Hematopoiesis Mutations Increase Risk of Alzheimer’s Disease with APOE ε3/ε3 Genotype. bioRxiv. sourceSupported

May combine two claims.

Other CHIP mutations, or identical mutations operating in different biological contexts, may exacerbate systemic inflammation, endothelial dysfunction, and cardiovascular pathology, indirectly increasing susceptibility to neurodegeneration through vascular injury and reduced cerebrovascular reserve.

“Conversely, other CHIP mutations, or identical mutations operating in different biological contexts, may exacerbate systemic inflammation, endothelial dysfunction, and cardiovascular pathology, indirectly increasing susceptibility to neurodegeneration through vascular injury and reduced cerebrovascular reserve [7,15].”

• cites [7] Trowbridge, 2023, Clonal hematopoiesis, aging and Alzheimer’s disease, Nat. Med. sourceNot checked — no full text of the source
• cites [15] Jaiswal, 2017, Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease, N. Engl. J. Med. sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

CHIP mutations originate in multipotent HSCs, but the clonal progeny is predominantly concentrated within the myeloid compartment, with a significantly lower mutational burden in lymphoid cells.

“CHIP mutations originate in multipotent HSCs, the clonal progeny is predominantly concentrated within the myeloid compartment, specifically affecting monocytes and granulocytes, with a significantly lower mutational burden observed in lymphoid cells [29].”

• cites [29] Arends, 2018, Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis, Leukemia sourceNot checked — no full text of the source

May combine two claims.

Mutated myeloid cells can infiltrate the central nervous system and modulate neuroinflammation and amyloid clearance.

“highlighting the ability of mutated myeloid cells to infiltrate the central nervous system and modulate neuroinflammation and amyloid clearance”

May combine two claims.

CHIP is not a simple protective factor, but a complex systemic modulator that reshapes the neurodegenerative and vascular drivers of cognitive decline.

“our review clarifies that CHIP is not a simple protective factor, but a complex systemic modulator that reshapes the neurodegenerative and vascular drivers of cognitive decline”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

VAF levels may correlate with the intensity of systemic inflammatory output.

“VAF levels may correlate with the intensity of systemic inflammatory output.”

Probably not a substantial claim: may not pass S4 (based).

CHIP may differentially influence AD and vascular contributions to cognitive impairment and dementia, shaping mixed dementia phenotypes.

“We propose that CHIP may differentially influence AD and vascular contributions to cognitive impairment and dementia, shaping mixed dementia phenotypes.”

May combine two claims.

DNMT3A and TET2 mutations are most prevalent in myeloid cells for TET2 and show a multilineage distribution for DNMT3A-carrying clones.

“the most frequent mutations DNMT3A and TET2 mutations, are most prevalent in myeloid cells for TET2 and show a multilineage distribution for DNMT3A-carrying clones [30].”

• cites [30] Buscarlet, 2018, Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A, Blood sourceNot checked — no full text of the source

May combine two claims.

DNMT3A primarily enhances HSC self-renewal and clonal longevity, whereas TET2 loss more characteristically drives a pro-inflammatory myeloid state, although these effects depend on mutation-specific characteristics.

“DNMT3A primarily enhances HSC self-renewal and clonal longevity, whereas TET2 loss more characteristically drives a pro-inflammatory myeloid state, although these effects remain dependent on mutation specific characteristics.”

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

CHIP represents a biologically plausible modifier of brain aging, with the potential to influence neurodegenerative trajectories through both immune-mediated and vascular mechanisms.

“CHIP represents a biologically plausible modifier of brain aging, with the potential to influence neurodegenerative trajectories through both immune-mediated and vascular mechanisms.”

May combine two claims.

Systemic inflammation and peripheral immune alterations have been linked to cognitive decline and neurodegeneration, suggesting dynamic neuroimmune crosstalk where peripheral hematopoietic signals propagate to the CNS.

“Beyond the central nervous system, systemic inflammation and peripheral immune alterations have been linked to cognitive decline and neurodegeneration, suggesting a dynamic neuroimmune crosstalk where peripheral hematopoietic signals propagate to the CNS to drive neurodegeneration.”

May combine two claims.

DNMT3A mutations cause focal DNA hypomethylation, which increases HSC self-renewal, while loss of TET2 leads to DNA hypermethylation and a hyper-inflammatory state.

“DNMT3A mutations cause focal DNA hypomethylation, which increases HSC self-renewal, while the loss of TET2 leads to DNA hypermethylation and a hyper-inflammatory state.”

May combine two claims.

Liu et al. observed a modest increase in the risk of any neurodegenerative disease among CHIP carriers, with stronger associations for vascular neurodegenerative diseases and ALS, but no significant association for Alzheimer's disease specifically.

“Liu et al. observed a modest increase in the risk of any neurodegenerative disease among CHIP carriers, with stronger associations for vascular neurodegenerative diseases and ALS; however, no significant association was detected for Alzheimer’s disease specifically [11]”

• cites [11] Liu, 2024, Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases, J. Intern. Med. sourceNot checked — no full text of the source

May combine two claims.

The lack of AD association in Liu et al. is likely constrained by the cohort's younger demographic and the use of ICD-based diagnostic adjudication, leading to underestimation of AD incidence and biomarker-confirmed cases.

“a finding likely constrained by the cohort’s younger demographic and the use of ICD-based diagnostic adjudication, which together lead to a significant underestimation of AD incidence and biomarker-confirmed cases.”

• cites [11] Liu, 2024, Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases, J. Intern. Med. sourceNot checked — no full text of the source

May combine two claims.

Competing risks play a decisive role: CHIP carriers experience increased cardiovascular morbidity and mortality, effectively limiting survival to ages at which clinical AD is most frequently diagnosed.

“First, competing risks play a decisive role: CHIP carriers experience increased cardiovascular morbidity and mortality, effectively limiting survival to ages at which clinical AD is most frequently diagnosed [4,7].”

• cites [4] Jaiswal, 2020, Clonal hematopoiesis and nonhematologic disorders, BloodNot checked yet

  Not checked in the free run.

• cites [7] Trowbridge, 2023, Clonal hematopoiesis, aging and Alzheimer’s disease, Nat. Med. sourceNot checked — no full text of the source

May combine two claims.

The downstream consequences of CHIP differ substantially between vascular and neurodegenerative environments, where shared clonal variants may promote deleterious systemic inflammation while simultaneously enhancing protective amyloid clearance within the brain.

“these findings reveal that the downstream consequences of CHIP differ substantially between vascular and neurodegenerative environments, where shared clonal variants may promote deleterious systemic inflammation while simultaneously enhancing protective amyloid clearance within the brain [30].”

• cites [30] Buscarlet, 2018, Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A, Blood sourceNot checked — no full text of the source

May combine two claims.

Discrepancies in CHIP-AD findings likely reflect differences in clone size thresholds, driver gene composition, APOE stratification approach, study design, and outcome definition.

“These discrepancies likely reflect differences in clone size thresholds, driver gene composition, the author’s APOE stratification approach, study design, and outcome definition”

May combine two claims.

This diagnostic competition may obscure the underlying pathology of Alzheimer's disease and contribute to divergent associations across studies using different diagnostic frameworks or outcome definitions for participant recruitment.

“This diagnostic competition may obscure the underlying pathology of Alzheimer’s disease and contribute to divergent associations across studies using different diagnostic frameworks or outcome definitions for participant recruitment.”

Classified as probably not a substantial claim.

The literature linking CHIP to Alzheimer's disease has produced heterogeneous and at times seemingly contradictory results.

“The emerging literature linking CHIP to AD has produced heterogeneous and, at times, seemingly contradictory results.”

May combine two claims.

APOE status is a fundamental biological modifier rather than a mere statistical confounder.

“Ultimately, these discrepancies underscore that APOE status is a fundamental biological modifier rather than a mere statistical confounder”

May combine two claims.

CHIP has emerged as a significant yet complex biological feature of aging that intersects pathways relevant to AD.

“CHIP has emerged as a significant yet complex biological feature of aging that intersects pathways relevant to AD.”

May combine two claims.

These deleterious effects are particularly relevant in settings of high vascular burden, advanced age, or impaired blood-brain barrier integrity, where CHIP-associated vascular disease may dominate clinical outcomes and promote vascular or mixed dementia phenotypes.

“These deleterious effects are particularly relevant in settings of high vascular burden, advanced age, or impaired blood–brain barrier integrity, where CHIP-associated vascular disease may dominate clinical outcomes and promote vascular or mixed dementia phenotypes.”

May combine two claims.

Clonal burden may be a driver of disease association, suggesting that a threshold effect may exist where only larger clones possess the systemic impact necessary to influence neurodegenerative progression.

“Crucially, these findings indicate that clonal burden may be a driver of disease association, suggesting that a threshold effect may exist where only larger clones possess the systemic impact necessary to influence neurodegenerative progression.”

May combine two claims.

Recent geroscience syntheses have identified clonal hematopoiesis as a systemic driver of inflammaging and vascular aging, with pleiotropic effects observed across organ systems, including the brain.

“Recent geroscience syntheses have identified clonal hematopoiesis as a systemic driver of inflammaging and vascular aging, with pleiotropic effects observed across organ systems, including the brain [7].”

• cites [7] Trowbridge, 2023, Clonal hematopoiesis, aging and Alzheimer’s disease, Nat. Med. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

In some settings, particularly for large clones and specific mutations such as TET2, CHIP-associated immune alterations may enhance amyloid clearance and modulate neuroinflammation.

“In some settings, particularly for large clones and specific mutations such as TET2, CHIP-associated immune alterations may enhance amyloid clearance and modulate neuroinflammation.”

Probably not a substantial claim: may not pass S2 (checkable).

Failure to account for these effects risks misinterpreting both protective and deleterious associations.

“Failure to account for these effects risks misinterpreting both protective and deleterious associations.”

May combine two claims.

CHIP does not function as a binary risk factor but rather acts as a multidimensional modifier, where the magnitude of the clonal burden and gene-specific identification help predict clinical outcomes.

“Importantly, CHIP does not function as a binary risk factor but rather acts as a multidimensional modifier, where the magnitude of the clonal burden and gene-specific identification help predict clinical outcomes.”

Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

Positioning CHIP as a context-dependent modifier provides a more coherent explanation of existing data than traditional binary models.

“Positioning CHIP as a context-dependent modifier provides a more coherent explanation of existing data than traditional binary models.”

Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

The discrepancies in the CHIP-AD literature likely reflect methodological differences across studies rather than true biological inconsistency.

“These discrepancies likely reflect methodological differences across studies rather than true biological inconsistency.”

Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

This model provides a coherent biological framework for reconciling seemingly contradictory findings across studies, including divergent results obtained from shared cohorts such as the ADSP.

“Importantly, this model provides a coherent biological framework for reconciling seemingly contradictory findings across studies, including divergent results obtained from shared cohorts such as the ADSP.”

May combine two claims.

CHIP may simultaneously exacerbate vascular brain injury while modulating neuroimmune pathways relevant to amyloid handling, yielding net effects that vary according to genetic background, clonal burden, and competing pathologies.

“CHIP may simultaneously exacerbate vascular brain injury while modulating neuroimmune pathways relevant to amyloid handling, yielding net effects that vary according to genetic background, clonal burden, and competing pathologies.”

May combine two claims.

Such differences in APOE adjustment and stratification can alter effect estimates, reduce statistical power, and produce discordant results, particularly in replication cohorts such as the ADSP.

“Such differences can alter effect estimates, reduce statistical power, and produce discordant results, particularly in replication cohorts such as the ADSP.”

May combine two claims.

In other settings, CHIP-driven vascular disease, stroke, and cerebral small vessel pathology may dominate, shifting the clinical presentation toward vascular or mixed dementia phenotypes and complicating diagnostic classification.

“In others, CHIP-driven vascular disease, stroke, and cerebral small vessel pathology may dominate, shifting the clinical presentation toward vascular or mixed dementia phenotypes and complicating diagnostic classification.”

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

Certain CHIP mutations induce immune states that enhance phagocytic function, promote amyloid clearance, and attenuate maladaptive neuroinflammation.

“Under this paradigm, certain CHIP mutations induce immune states that enhance phagocytic function, promote amyloid clearance, and attenuate maladaptive neuroinflammation.”

May combine two claims.

While CHIP-associated immune alterations may be protective in some contexts, they are clearly pathogenic in others, particularly with respect to vascular disease.

“While CHIP-associated immune alterations may be protective in some contexts, they are clearly pathogenic in others, particularly with respect to vascular disease.”